US Patent

US11079379 — Methods of treating transthyretin (TTR) mediated amyloidosis

Method of Use · Assigned to Alnylam Pharmaceuticals Inc · Expires 2035-08-27 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for reducing or arresting neuropathy impairment in human subjects by administering a transthyretin-inhibiting composition.

USPTO Abstract

Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.

Drugs covered by this patent

Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2378`	—	Onpattro

Patent Metadata

Patent number: US11079379
Jurisdiction: US
Classification: Method of Use
Expires: 2035-08-27
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.